Sirio Pharma, a global contract development and manufacturing organization specializing in nutraceuticals, announced in a recent press release that it recorded strong revenue growth in the Asia-Pacific region. The company confirmed plans to build a new manufacturing facility in Thailand, scheduled to begin construction in the fourth quarter of 2025.
Southeast Asia has experienced a steady rise in demand for nutraceutical products, particularly in Thailand, Singapore, Indonesia, and Australia. To address changing consumer preferences, Sirio is expanding its production capacity in the region. In Australia, demand has increased for high-dosage sports nutrition gummies, fish oil products, and multivitamins. Singapore has seen growth in collagen-based beauty supplements, sour-flavored gummies, and biotin products.
The company stated that markets in India, Thailand, and Indonesia are expected to expand further in the coming years. In Australia, consumers are shifting toward muscle gain and recovery products and are seeking convenient alternatives to powders. To meet this demand, Sirio has introduced high-dosage gummies containing creatine, protein, and BCAAs. Thailand is experiencing a rise in interest in micro effervescent vitamins and sports gummies as active lifestyles become more common. In Indonesia, demand has centered on halal-certified supplements and formulations stable in Zone IVB climates. In India, consumers have shown interest in vegetarian soft gels as well as collagen and biotin-based beauty supplements.
(Source: Nutritional Outlook)
